Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports. A number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback